Anebulo Pharmaceuticals (ANEB) Total Current Liabilities (2020 - 2021)
Anebulo Pharmaceuticals (ANEB) posted quarterly Total Current Liabilities of $293166.0 for Q1 2021, up 30.96% quarter-over-quarter from $223865.0 in Q2 2020.
Anebulo Pharmaceuticals (ANEB) Total Current Liabilities (2020 - 2021) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Total Current Liabilities for 2 consecutive years, with $293166.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Total Current Liabilities changed N/A year-over-year to $293166.0; the TTM figure through Mar 2021 stood at $293166.0 (changed N/A YoY), while the FY2020 annual figure was $223865.0, changed N/A from the prior year.
- Total Current Liabilities climbed to $293166.0 in Q1 2021 per ANEB's latest filing, from $223865.0 in the prior quarter.
- Across five years, Total Current Liabilities topped out at $293166.0 in Q1 2021 and bottomed at $223865.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 293,166.00 |
| Jun 30, 2020 | 223,865.00 |